Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $10 from $9 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics price target raised to $9 from $4 at Barclays
- Largest borrow rate increases among liquid names
- Iovance Biotherapeutics price target raised to $1.50 from $1 at Goldman Sachs
- Iovance Biotherapeutics Reports Strong Q3 2025 Growth
- Iovance Biotherapeutics Reports Positive Earnings Amid Growth